MedTrace Logo

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

NCT01339871 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2017-06-16

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

Conditions

Interventions

DRUG

Pazopanib

Starting dose 400 mg orally daily of 28 day cycle.

DRUG

Vorinostat

Starting dose 100 mg orally daily of 28 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Siqing Fu, MD,PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-20
Primary Completion
2017-06-07
Completion
2017-06-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01339871 on ClinicalTrials.gov